A Study to Identify Participants With Urothelial Cancer & Fibroblast

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Terminated	`NCT01663285` - Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)	Phase 2
Recruiting	`NCT00872495` - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Terminated	`NCT04629339` - Study of INCB086550 in Select Solid Tumors	Phase 2
Recruiting	`NCT04114136` - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Phase 2
Completed	`NCT03219333` - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Phase 2
Terminated	`NCT04501094` - A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma	Phase 2
Recruiting	`NCT04923178` - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Completed	`NCT02256436` - A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)	Phase 3
Completed	`NCT01206426` - Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
Terminated	`NCT00995488` - Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer	Phase 2
Active, not recruiting	`NCT03425201` - Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)	Phase 1/Phase 2
Active, not recruiting	`NCT03288545` - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03983954` - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT04180371` - Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression	Phase 1/Phase 2
Active, not recruiting	`NCT02891161` - Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder	Phase 1/Phase 2
Withdrawn	`NCT01700010` - Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer	Phase 2
Active, not recruiting	`NCT02516241` - Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	Phase 3
Active, not recruiting	`NCT04152018` - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.	Phase 1

NCT number	NCT03955913
Study type	Observational
Source	Janssen Research & Development, LLC
Contact
Status	Completed
Phase
Start date	August 1, 2019
Completion date	September 19, 2022

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms